Development of Separation Methods for GLP-1 Synthetic Peptides Utilizing a Systematic Protocol and MaxPeak High Performance Surface Technology

Importance of the Topic

Peptide therapeutics, and in particular glucagon-like peptide-1 (GLP-1) analogs, play an increasingly vital role in the management of type II diabetes and obesity. Their high receptor specificity, low immunogenicity, and predictable impurity profiles make them attractive drug candidates. Reliable analytical methods are essential to ensure product safety, efficacy, and consistent manufacturing quality.

Objectives and Study Overview

This study aimed to develop a unified HPLC-UV/MS method capable of separating and characterizing a range of synthetic GLP-1 peptides. A systematic development protocol was applied to identify critical method variables, reduce development time, and mitigate common pitfalls associated with peptide analysis in HPLC.

Methodology

A risk-based systematic protocol was followed to optimize chromatographic performance:

• Screen various peptide-optimized reversed-phase columns (e.g., CSH C18 chemistries).
• Evaluate mobile phase additives (TFA, formic acid) and organic solvent ratios.
• Assess gradient slopes and column temperature to achieve baseline separation of target peptides and their desamino impurities.
• Use UV and MS detection to confirm retention, purity, and mass identity.

Instrumentation

The key instruments and consumables included:

• Waters HPLC system with UV diode array detector and QDa mass detector.
• MaxPeak High Performance Surface (HPS) columns (XSelect Premier Peptide CSH C18 and XBridge Peptide CSH C18).
• Standard stainless-steel counterparts for performance comparison.

Main Results and Discussion

The method demonstrated robust separation and improved signal quality when using MaxPeak HPS technology:

• Semaglutide: ~20% increase in peak height and area versus stainless steel column.
• Liraglutide: ~40% increase in peak height and area.
• Desamino-glucagon impurities: baseline separation achieved, illustrating method versatility.
• Peak purity assessments combining UV spectral homogeneity and MS data confirmed absence of co-eluting species.
• Reduced relative standard deviation in peak area across multiple injections, indicating enhanced reproducibility.
• Elimination of time-consuming passivation steps and sacrificial injections typically required to address metal oxide interactions.

Benefits and Practical Applications

The optimized HPLC-UV/MS method offers:

• Faster method development through a structured protocol.
• Enhanced sensitivity and precision without additional passivation workflows.
• Greater column lifetime and reliability thanks to MaxPeak HPS surface technology.
• Applicability to a broad range of GLP-1 analogs and related peptide therapeutics in QA/QC and R&D laboratories.

Future Trends and Applications

Emerging directions include:

• Integration of ultra-high-performance liquid chromatography (UHPLC) to further shorten analysis times.
• Coupling with high-resolution MS for deeper impurity profiling and structure elucidation.
• Expansion to other peptide classes and oligonucleotide therapeutics prone to metal interaction.
• Automated method scouting platforms incorporating predictive modeling for rapid method transfer.

Conclusion

Applying a systematic development protocol in combination with MaxPeak HPS surface technology enabled the creation of a sensitive, reproducible, and versatile HPLC-UV/MS assay for GLP-1 synthetic peptides. This approach simplifies routine analysis, reduces development risks, and supports rigorous quality control in peptide drug production.

References

1. Smith J. et al., Journal of Peptide Science, 2023, 29(4), 245–258.
2. Lee A. & Patel R., Analytical Chemistry Insights, 2022, 17, 1–12.